The NBA got viewers for Christmas, even while going up against NFL games. The NBA's five-game Christmas lineup was the league's most-watched in five years, with the games averaging about 5.25 million viewers per game across ABC, ESPN and its platforms, the league said Thursday based on Nielsen's preliminary numbers. It's an 84% rise over the NBA's Christmas numbers from 2023. The Los Angeles Lakers’ 115-113 victory over the Golden State Warriors — a game pitting Olympic teammates LeBron James and Stephen Curry — averaged 7.76 million viewers and peaked with about 8.32 million viewers toward the end of the contest, the league said. Those numbers represent the most-watched NBA regular season game in five years. “I love the NFL,” James said in his televised postgame interview Wednesday night. “But Christmas is our day.” The NBA said all five Christmas games on its schedule — San Antonio at New York in Victor Wembanyama's holiday debut, Minnesota at Dallas, Philadelphia at Boston, Denver at Phoenix and Lakers-Warriors — saw year-over-year viewership increases. Wednesday's numbers pushed NBA viewership for the season across ESPN platforms to up 4% over last season. The league also saw more than 500 million video views on its social media platforms Wednesday, a new record. For the NBA, those are all good signs amid cries that NBA viewership is hurting. “Ratings are down a bit at beginning of the season. But cable television viewership is down double digits so far this year versus last year," NBA Commissioner Adam Silver said earlier this month. “You know, we’re almost at the inflection point where people are watching more programing on streaming than they are on traditional television. And it’s a reason why for our new television deals, which we enter into next year, every game is going to be available on a streaming service.” Part of that new package of television deals that the NBA is entering into next season also increases the number of regular season games broadcast on television from 15 to 75. AP NBA: https://www.apnews.com/hub/NBA
The United States is expected to announce that it will send 1.25 billion dollars (£1 billion) in military assistance to Ukraine, US officials said on Friday, as the Biden administration pushes to get as much aid to Kyiv as possible before leaving office on January 20. The large package of aid includes a significant amount of munitions, including for the National Advanced Surface-to-Air Missile Systems and the Hawk air defence system. It also will provide Stinger missiles and 155mm and 105mm artillery rounds, officials said. The officials, who said they expect the announcement to be made on Monday, spoke on condition of anonymity to provide details not yet made public. The new aid comes as Russia launched a barrage of attacks against Ukraine’s power facilities in recent days, although Ukraine has said it intercepted a significant number of the missiles and drones. Russian and Ukrainian forces are also still in a bitter battle around the Russian border region of Kursk, where Moscow has sent thousands of North Korean troops to help reclaim territory taken by Ukraine. Earlier this month, senior defence officials acknowledged that the US Defence Department may not be able to send all of the remaining 5.6 billion dollars (£4.5 billion) in Pentagon weapons and equipment stocks passed by Congress for Ukraine before President-elect Donald Trump is sworn in. Mr Trump has talked about getting some type of negotiated settlement between Ukraine and Russia, and spoken about his relationship with Russian President Vladimir Putin. Many US and European leaders are concerned that it might result in a poor deal for Ukraine and they worry that he will not provide Ukraine with all the weapons funding approved by Congress. The aid in the new package is in presidential drawdown authority, which allows the Pentagon to take weapons off the shelves and send them quickly to Ukraine. This latest assistance would reduce the remaining amount to about 4.35 billion dollars (£3.46 billion). Officials have said they hope that an influx of aid will help strengthen Ukraine’s hand, should Ukrainian president Volodymyr Zelensky decide it is time to negotiate. One senior defence official said that while the US will continue to provide weapons to Ukraine until January 20, there may well be funds remaining that will be available for the incoming Trump administration to spend. According to the Pentagon, there is also about 1.2 billion dollars (£0.9 billion) remaining in longer-term funding through the Ukraine Security Assistance Initiative, which is used to pay for weapons contracts that would not be delivered for a year or more. Officials have said the administration anticipates releasing all of that money before the end of the calendar year. If the new package is included, the US will have provided more than 64 billion dollars (£50.8 billion) in security assistance to Ukraine since Russia invaded in February 2022.
Traffic police taking steps to curb rising mishaps
NoneThe NFL has issued a security warning to players about a criminal network targeting their homes. Players have been urged to ramp up security and take care about what they post on social media. It comes after the homes of Kansas City Chiefs stars Patrick Mahomes and Travis Kelce were burgled last month, while a property owned by Dallas Cowboys' Linval Joseph was targeted last week. An NFL security memo about the issue has been sent out to team security directors and the players' union. Reporting on the memo, the NFL website said it was understood the criminal organisation "use public records to find players' addresses and conduct extensive surveillance". "Then, by tracking team schedules and the social media accounts of players and their families, they wait until homes are empty - often during games." Players have also been asked to make it look like someone is at home when they are out, by leaving lights or a television on, for example. "I can't get into too many of the details because the investigation is still ongoing," Mahomes said when asked about the break in. "But obviously something that you don't want to happen to really anybody, but obviously yourself."
Watch moment dad of sex abuse teacher Brittany Zamora’s 13-year-old victim confronts her & dubs her a ‘f***ing monster’NBA's Christmas Day ratings skyrocket, even going up against NFL games
New genetic test will help safeguard quinoa
'Kid-preneurs' Partner with Community Businesses for Food, Toy Drive
Sunday, 1 p.m. EST, Fox BetMGM NFL Odds: Eagles by 7 1/2 Against the spread: Dallas 6-9; Philadelphia 9-6 Series record: Cowboys lead 74-58. Last meeting: Jalen Hurts threw two touchdowns and ran for two more in the Eagles’ 34-6 rout of the Cowboys at Dallas on Nov. 10. Last week: Cowboys defeated the Buccaneers 26-24; Eagles lost 36-33 at Washington. Cowboys offense: overall (16), rush (28), pass (10), scoring (20) Cowboys defense: overall (27), rush (27), pass (21), scoring (30) Eagles offense: overall (6), rush (1), pass (31), scoring (8) Eagles defense: overall (1), rush (9), pass (2), scoring (5) Turnover differential: Cowboys minus-3; Eagles plus-6 RB Saquon Barkley is 162 yards shy of becoming the ninth player in NFL history to rush for 2,000 yards in a season and needs 268 yards to break Eric Dickerson’s single-season rushing record of 2,105 yards, set in 1984. In his past five games, QB Cooper Rush has passed for nine touchdowns and one interception, looking more comfortable of late after taking over for Dak Prescott in November. Rush is 9-2 as a starter against teams that are not the Eagles. Dallas’s rushing defense vs. Barkley. Can anyone stop him? The Cowboys will be the latest to try to corral Barkley, who has 1,838 rushing yards and 2,114 scrimmage yards, both of which lead the NFL. Dallas ranks 28th in the NFL in rushing defense, allowing an average of 135.9 yards a game. Philadelphia, behind Barkley’s stellar play, tops the league at 187.9 yards a game on the ground. Cowboys: WR CeeDee Lamb will miss the final two games after getting shut down over the sprained right shoulder he's been dealing with the second half of the season. ... LB Eric Kendricks (calf) warmed up but wasn’t able to play against Tampa Bay last week. Eagles: Hurts is in concussion protocol after leaving the game following a 13-yard scramble with 9:52 left in the first quarter last week. ... DE Josh Sweat (ankle) and Jordan Davis also left the game at Washington early. ... QB Ian Book was signed to the practice squad Thursday. The Cowboys made the playoffs in each of the previous three seasons, but were eliminated prior to their game against Tampa Bay last week when the Commanders came back from a 13-point, fourth-quarter deficit to beat Philadelphia. ... Dallas is 5-2 on the road. ... The Eagles can clinch the NFC East and one of the conference's top two seeds with a victory. ... On Jan. 11, 1981, the Eagles defeated the Cowboys 20-7 at their former home, Veterans Stadium. Wilbert Montgomery rushed for a 42-yard touchdown to give Philadelphia an early lead that propelled the Eagles to their first Super Bowl appearance. LB Micah Parsons needs half a sack to reach double digits in sacks for the fourth straight season to begin his career and would become just the fifth player to accomplish the feat in NFL history. ... K Brandon Aubrey made a 53-yard and two 58-yard field goals against the Buccaneers, upping his league-leading total to 14 made of 50-plus yards. ... Kenny Pickett went 14 of 24 for 143 yards and a TD in relief of Hurts last week. If he can’t go because of the rib injury and Hurts remains unavailable, Philadelphia could turn to third-stringer Tanner McKee, a 2023 sixth-round pick. Pickett, a 2022 first-round pick, is no stranger to starting, going 14-10 as Pittsburgh’s QB earlier in his career. ... Defensive back C.J. Gardner-Johnson was ejected against Washington for committing two unsportsmanlike penalties. ... The Eagles already set a team record for rushing yards in a season with 2,818, and they are within four rushing touchdowns of tying the club’s best single-season mark of 32, set in 2022. ... Barkley needs just 33 yards from scrimmage to break McCoy’s mark of 2,146 scrimmage yards, set in 2013. ... WR A.J. Brown leads the NFL with 16.3 yards a catch and ranks ninth in the league with 1,043 receiving yards, joining Mike Quick (1983–85) as the only Philadelphia players to have three consecutive 1,000-yard receiving seasons. Philadelphia’s defense is tied for ninth in the NFL with a plus-6 turnover margin. With Hurts possibly sidelined, Philadelphia giving up an uncharacteristic 36 points last week and the chance to clinch the division, the Eagles defense likely will be extra motivated to have a good performance against a Dallas offense that ranks 21st in the league in points. AP NFL: https://apnews.com/hub/NFLShould the U.S. increase immigration levels for highly skilled workers?
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |